We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

62 hedge funds and large institutions have $110M invested in Ovid Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 17

1% more capital invested

Capital invested by funds: $109M → $110M (+$1.08M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.03% less ownership

Funds ownership: 49.96% → 49.92% (-0.03%)

7% less funds holding

Funds holding: 67 → 62 (-5)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
62
Holders Change
-5
Holders Change %
-7.46%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
22
Reduced
17
Closed
12
Calls
$231K
Puts
–
Net Calls
+$231K
Net Calls Change
-$966K

Top Buyers

Rank Fund Capital Flow
1
CA
CHI Advisors
New York
+$1.42M
2
DCM
Driehaus Capital Management
Illinois
+$1.13M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$772K
4
BI
BVF Inc
California
+$692K
5
SCM
Stonepine Capital Management
Oregon
+$667K

Top Sellers

Rank Fund Capital Flow
1
PIM
Platinum Investment Management
Australia
-$2.46M
2
GC
Globeflex Capital
California
-$289K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$252K
4
AFM
Anson Funds Management
Texas
-$176K
5
B
Bailard
California
-$154K
Name Holding Trade Value Shares
Change 		Change in
Stake
Boston Partners
26
Boston Partners
Massachusetts
$265K – – –
Northern Trust
27
Northern Trust
Illinois
$263K -$11.2K -3,546 -4%
First Trust Advisors
28
First Trust Advisors
Illinois
$252K -$14.6K -4,655 -5%
BFM
29
Boothbay Fund Management
New York
$224K – – –
Jane Street
30
Jane Street
New York
$199K +$200K +63,508 New
William Blair & Company
31
William Blair & Company
Illinois
$183K -$102K -32,487 -36%
American Century Companies
32
American Century Companies
Missouri
$179K +$31.4K +9,994 +21%
Man Group
33
Man Group
United Kingdom
$150K +$151K +47,863 New
Bank of Nova Scotia
34
Bank of Nova Scotia
Ontario, Canada
$149K +$16.1K +5,124 +12%
Goldman Sachs
35
Goldman Sachs
New York
$143K -$12.7K -4,042 -8%
OSAM
36
O'Shaughnessy Asset Management
Connecticut
$132K +$132K +42,028 New
Bank of America
37
Bank of America
North Carolina
$131K +$125K +39,875 +2,314%
Citadel Advisors
38
Citadel Advisors
Florida
$120K -$126K -40,160 -51%
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$119K – – –
Two Sigma Advisers
40
Two Sigma Advisers
New York
$108K -$39.9K -12,700 -27%
First Manhattan
41
First Manhattan
New York
$81K +$56.6K +18,000 +225%
Charles Schwab
42
Charles Schwab
California
$62K – – –
Dimensional Fund Advisors
43
Dimensional Fund Advisors
Texas
$61K – – –
MFS
44
Mirabella Financial Services
United Kingdom
$61K +$61.3K +19,500 New
Morgan Stanley
45
Morgan Stanley
New York
$60K -$7.53K -2,395 -11%
CANY
46
Caxton Associates (New York)
New York
$55K – – –
SFO
47
Stokes Family Office
Louisiana
$48K +$48K +15,246 New
UBS Group
48
UBS Group
Switzerland
$47K -$13.5K -4,277 -22%
RA
49
Royce & Associates
New York
$37K +$37.2K +11,811 New
JP Morgan Chase
50
JP Morgan Chase
New York
$25K +$6.08K +1,934 +32%
1
2
3

OVID Hedge Fund Activity: Q1 2022 in Review

62 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q1 2022, worth a combined $110M — up 0.99% from $109M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of OVID and 7 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 22 added.

The largest buyer was CHI Advisors, adding an estimated $1.42M. The largest seller was Platinum Investment Management, exiting entirely with an estimated $2.46M sold.

  • 62 institutional investors held Ovid Therapeutics (OVID) as of Q1 2022, down from 67 in Q4 2021.
  • Funds reported $110M of Ovid Therapeutics stock for Q1 2022, up 0.99% quarter-over-quarter.
  • 7 funds opened new Ovid Therapeutics positions in Q1 2022 and 12 closed out, a net change of -5 holders.
  • The largest Ovid Therapeutics buyer in Q1 2022 was CHI Advisors, an estimated $1.42M added.
  • The largest Ovid Therapeutics seller in Q1 2022 was Platinum Investment Management, an estimated $2.46M sold.

Based on aggregated 13F filings for Q1 2022.